Biomedical applications of bisphosphonates

被引:160
作者
Giger, Elisabeth V. [1 ]
Castagner, Bastien [1 ]
Leroux, Jean-Christophe [1 ]
机构
[1] ETH, Dept Chem & Appl Biosci, Inst Pharmaceut Sci, CH-8093 Zurich, Switzerland
关键词
Bisphosphonate; Osteoporosis; Targeting; Implant; Nanomedicine; Drug conjugates; NITROGEN-CONTAINING BISPHOSPHONATE; REDUCES NEOINTIMAL FORMATION; TUMOR-ASSOCIATED MACROPHAGES; SELF-ASSEMBLY NANOPARTICLES; CALCIUM-PHOSPHATE CRYSTALS; TARGETING BONE METASTASES; IRON-OXIDE NANOPARTICLES; IN-VITRO EVALUATION; ZOLEDRONIC ACID; MINERAL AFFINITY;
D O I
10.1016/j.jconrel.2013.01.032
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Since their discovery over 100 years ago, bisphosphonates have been used industrially as corrosion inhibitors and complexing agents. With the discovery of their pharmacological activity in the late 1960s, implicating their high affinity for hydroxyapatite, bisphosphonates have been employed in the treatment of bone diseases and as targeting agents for colloids and drugs. They have notably been investigated for the treatment of Paget's disease, osteoporosis, bone metastases, malignancy-associated hypercalcemia, and pediatric bone diseases. Currently, they are first-line medications for several of these diseases and are taken by millions of patients worldwide, mostly postmenopausal women. A major problem associated with their use is their low oral bioavailability. Several delivery systems have been proposed to improve their absorption and to direct them to sites other than bone tissues. Beyond their important pharmacological role, the medical applications of bisphosphonates are numerous. In addition, their metal-chelating properties have been exploited to coat and stabilize implants, nanoparticulates, and contrast agents. In this contribution, we review the pharmacological and clinical uses of bisphosphonates and highlight their novel applications in the pharmaceutical and biomedical fields. (C) 2013 Elsevier B. V. All rights reserved.
引用
收藏
页码:175 / 188
页数:14
相关论文
共 190 条
[1]   Guidance on the use of bisphosphonates in solid tumours:: recommendations of an international expert panel [J].
Aapro, M. ;
Abrahamsson, P. A. ;
Body, J. J. ;
Coleman, R. E. ;
Colomer, R. ;
Costa, L. ;
Crino, L. ;
Dirix, L. ;
Gnant, M. ;
Gralow, J. ;
Hadji, P. ;
Hortobagyi, G. N. ;
Jonat, W. ;
Lipton, A. ;
Monnier, A. ;
Paterson, A. H. G. ;
Rizzoli, R. ;
Saad, F. ;
Thuerlimann, B. .
ANNALS OF ONCOLOGY, 2008, 19 (03) :420-432
[2]   A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg [J].
Abelson, Abby .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (03) :695-705
[3]   Adverse Effects of Bisphosphonates [J].
Abrahamsen, Bo .
CALCIFIED TISSUE INTERNATIONAL, 2010, 86 (06) :421-435
[4]   Local bisphosphonate release versus hydroxyapatite coating for stainless steel screw fixation in rat tibiae [J].
Agholme, F. ;
Andersson, T. ;
Tengvall, P. ;
Aspenberg, P. .
JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE, 2012, 23 (03) :743-752
[5]   Bisphosphonate derivatized polyurethanes resist calcification [J].
Alferiev, I ;
Vyavahare, N ;
Song, CX ;
Connolly, J ;
Hinson, JT ;
Lu, ZB ;
Tallapragada, S ;
Bianco, R ;
Levy, R .
BIOMATERIALS, 2001, 22 (19) :2683-2693
[6]   Synthesis of calcium phosphate-binding liposome for drug delivery [J].
Anada, Takahisa ;
Takeda, Yoichi ;
Honda, Yoshitomo ;
Sakurai, Kazuo ;
Suzuki, Osamu .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) :4148-4150
[7]   PRELIMINARY-OBSERVATIONS OF A FORM OF COHERENCE THERAPY FOR OSTEOPOROSIS [J].
ANDERSON, C ;
CAPE, RDT ;
CRILLY, RG ;
HODSMAN, AB ;
WOLFE, BMJ .
CALCIFIED TISSUE INTERNATIONAL, 1984, 36 (03) :341-343
[8]   Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis [J].
Arns, Steve ;
Gibe, Romelo ;
Moreau, Anne ;
Morshed, M. Monzur ;
Young, Robert N. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (06) :2131-2140
[9]   Age-related differences in the temporal and spatial regulation of matrix metalloproteinases (MMPs) in normal skin and acute cutaneous wounds of healthy humans [J].
Ashcroft, GS ;
Horan, MA ;
Herrick, SE ;
Tarnuzzer, RW ;
Schultz, GS ;
Ferguson, MWJ .
CELL AND TISSUE RESEARCH, 1997, 290 (03) :581-591
[10]   The Use of Zoledronic Acid in Pediatric Cancer Patients [J].
August, Keith J. ;
Dalton, Amanda ;
Katzenstein, Howard M. ;
George, Bradley ;
Olson, Thomas A. ;
Wasilewski-Masker, Karen ;
Rapkin, Louis B. .
PEDIATRIC BLOOD & CANCER, 2011, 56 (04) :610-614